Decreased Expression of Human Class II Antigens on Monocytes from Patients with Acquired Immune Deficiency Syndrome

Increased Expression with Interferon-γ

Wytra Heagy, Vicki E. Kelley, Terry B. Strom, Kenneth Mayer, Howard M. Shapiro, Richard Mandel, and Robert Finberg

Dana-Farber Cancer Institute, Laboratory of Infectious Diseases and Departments of Medicine and Pathology, Harvard Medical School; Brigham and Women’s Hospital and Harvard Medical School, Department of Medicine; Laboratory of Immunogenetics and Transplantation, Beth Israel Hospital, Boston, Massachusetts 02115; Brown University; Department of Medicine, Providence, Rhode Island 02912; Fenway Health Care Center; and Center for Blood Research, Boston, Massachusetts 02115

Abstract. The expression of HLA-DR (a class II histocompatibility antigen) on monocytes isolated from the peripheral blood of normal individuals and patients with acquired immune deficiency syndrome (AIDS) was investigated by the use of dual fluorescent staining and cytofluorometry. In animal models the absence of class II positive monocytes is linked to a failure of T cells to respond to antigens.

We now report that patients with AIDS have a paucity of HLA-DR+ monocytes. The percentage of HLA-DR+ monocytes among eight normal individuals ranged from 49.3 to 95.0%+, and only one individual had <50% HLA-DR+ monocytes. HLA-DR expression on monocytes from homosexual male patients with lymphadenopathy was similar to that of normal subjects (range, 58.0 to 97.4%+). In contrast, seven of nine patients with AIDS had <50% HLA-DR+ monocytes (range, 13.4 to 78.8%+). The in vitro incubation of monocytes from AIDS patients with cloned human interferon-γ resulted in an increase of the expression of HLA-DR to near normal levels.

Address reprint requests to Dr. Heagy, Laboratory of Infectious Diseases, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115.

Received for publication 19 March 1984 and in revised form 15 June 1984.

Introduction

Acquired immunodeficiency syndrome (AIDS)1 is a recently described, lethal disease characterized by quantitative, as well as qualitative, abnormalities in subpopulations of T lymphocytes, and by infections not seen in normal hosts including infection with Pneumocystis carinii, disseminated toxoplasmosis, and cytomegalovirus (CMV) infection (1-8). The high incidence of neoplasm, especially Kaposi’s sarcoma (3-4), may reflect an inadequate immune response to oncogenic viruses. Patients with AIDS are subject to infection with Herpes group viruses. Disseminated viral infections with herpes simplex, varicella zoster, and CMV are common (7-8), and human T cell leukemia virus has been identified in some patients (9-12).

Patients with AIDS have T lymphocyte abnormalities including: (a) a reduced percentage of T3+ cells in the peripheral blood; (b) inverted ratios of T4+/T8+ cells; and (c) defective cellular immune functions (1-6, 13). In vitro T lymphocyte responses to specific antigens and mitogens are reduced and natural killer cell activity is decreased (6, 14). The factors underlying these abnormalities are not understood.

HLA-DR, a class II human major histocompatibility complex (MHC) antigen (homologous to mouse la), is a glycoprotein expressed on B lymphocytes and certain immune cells serving an accessory (antigen-presenting) role within the immune system, but not on other cells (15-19). Recently, gamma-interferon (IFN-γ) has been shown to induce expression of

1. Abbreviations used in this paper: AIDS, acquired immune deficiency syndrome; CHO, Chinese hamster ovary; CMV, cytomegalovirus; FITC, fluorescein isothiocyanate; IFN-γ, gamma-interferon; IL-2, interleukin-2; MHC, major histocompatibility complex.

2089 Expression of Class II Antigens in AIDS
HLA-DR upon blood monocytes, human fetal monocytes, several myeloid leukemic cell lines, and endothelial cells (20–22).

In both humans and mice, the ability of T cells to respond to antigen is totally dependent upon interaction with class II MHC positive accessory cells (23–27). In the absence of such class II positive accessory cells, T cells fail to respond to viruses or nominal antigens; however, T cell function is restored by the addition of Ia+ cells (27–28). Since the HLA-DR antigen is a marker for human Ia, the absence of HLA-DR+ accessory cells could, in theory, cause a complete collapse in cellular immunity which would be reflected as a defect in the ability of T cells to respond to antigens. Consequently, we have examined HLA-DR on monocytes from patients with AIDS. Using a system that detects two-color fluorescence by cytofluorometry, we determined that monocytes harvested from the circulating blood of AIDS patients express reduced levels of HLA-DR.

The availability of recombinant DNA produced human IFN-γ allows us to consider this as a therapeutic modality. Because IFN-γ, a product of activated T cells, increases the expression of HLA-DR (20–22) we incubated monocytes obtained from patients with AIDS with cloned human IFN-γ. We found that in vitro treatment of monocytes obtained from AIDS patients with the cloned human IFN-γ increased the expression of HLA-DR to near-normal levels.

Methods

Subjects. The patients studied were homosexual men or intravenous drug users diagnosed as having AIDS or lymphadenopathy. The diagnoses and laboratory findings for patients with AIDS are listed in Table I. All patients with AIDS had biopsy proven pneumocystis pneumonia and/or Kaposi’s sarcoma. Patients with the lymphadenopathic syndrome were homosexual men with unexplained persistent lymphadenopathy (>3 mo) in two or more extraglandular sites without obvious infection. At the time of study none was receiving interferon or steroids (or other agents known to affect T cell function) except as noted (Table I).

Adherent cells. Mononuclear leukocytes were isolated under sterile conditions from 60–100 ml of heparinized peripheral blood by Ficoll-Hypaque density gradient centrifugation. 30-ml aliquots of blood were layered over 15 ml of lymphocyte separation medium (Litton Bionetics, Kensington, MD). After centrifugation, cells at the interface were collected, washed twice with M199 medium (MA Bioproducts, Walkersville, MD) supplemented with 5% fetal bovine serum (FBS) (Stérie Systems, Inc., Logan, Utah), and 2 mM glutamine and 100 U/ml penicillin-streptomycin (Gibco Laboratories Inc., Grand Island, NY). In initial studies cells were resuspended in M199 containing 20% FBS, plated into two 60-mm culture dishes (Falcon Labware, Div. of Becton-Dickinson & Co., Oxnard, CA), and incubated at 37°C in 5% CO2 for 16 h. In later studies cells were resuspended in RPMI 1640 (Gibco Laboratories Inc.) supplemented with 20% FBS and plated in 8-ml volumes into 100-mm dishes at densities of 15–25 × 106 cells/dish in order to increase the number of cells adhering to the tissue culture plates. To remove the nonadherent cells plates were washed twice with warm L-15 medium (Gibco Laboratories, Inc.). RPMI 1640 supplemented with 20% FBS was added to the adherent cells and incubations in 5% CO2, 37°C, were continued for an additional 2 d.

Adherent cells were obtained by washing twice with warmed (37°C) Ca++Mg++-free Hanks’ balanced salt solution (MA Bioproducts) and then incubating at 37°C for 10 min in 2.5–5 ml of trypsin-versene mixture (200 mg versene and 500 mg trypsin 1:250/liter in balanced salt solution; MA Bioproducts). The reaction was stopped by the addition of an equal volume of RPMI medium containing 20% FBS. Finally, these cells were transferred to 15-ml tubes and washed twice in RPMI medium.

Treatment with interferon. The human IFN-γ used in these studies was obtained from a constitutively secreting cloned Chinese hamster ovary (CHO) cell line transfected with plasmid containing the human IFN-γ gene (29). Control medium was derived from the same parent CHO line without the IFN-γ gene and thus did not produce IFN-γ. Cloning and expression of IFN-γ have been previously reported (29, 30). Adherent cells isolated from peripheral blood were incubated with the human IFN-γ as previously described for fetal monocytes (21). Cells were incubated in 5% CO2 at 37°C for 2 d in control medium or medium containing 50 U/ml of IFN-γ.

Antibody staining. In the course of the present study, we used several anti-human mouse monoclonal antibodies: LB3.1 (IgG 2b), which defines a haplootype shared (framework) HLA-DR determinant (21) (a gift of Drs. Peter Knudsen and Jack Strominger, Dana-Farber Cancer Institute); fluorescein isothiocyanate (FITC)-conjugated MO2 (lgM), a marker specific for adherent monocytes (31) (Coulter Immunology, Hialeah, FL); OKT4 (IgG2b), a marker for helper T cells (Ortho Diagnostics, Raritan, NJ); anti-Leu-1 phycoerythrin conjugate, a marker for T cells (Becton-Dickinson & Co., Mountain View, CA), and FITC-conjugated J13 (lgM), an antibody recognizing the human common acute lymphoblastic leukemia antigen (a gift of Dr. Robert Todd, Dana-Farber Cancer Institute).

Indirect cell staining of monoclonal antibodies was conducted by use of a sheep F(ab')2 anti-mouse Ig-Texas red (New England Nuclear, Boston, MA) or goat F(ab')2 anti-mouse Ig-FITC (Meloy Laboratories Inc., Springfield, VA).

In studies not using double labeling (see below) adherent cells were treated twice with a 1:10 dilution of OKT3 (32) (Ortho Diagnostics) for 30 min at 20°C followed by a 30-min incubation at 37°C in rabbit complement (Pel-Freeze Biologicals Rogers, AR).

In order to block nonspecific antibody binding by cellular Fc receptors, cells were preincubated in 1 ml of 50% AB human serum in phosphate-buffered saline (PBS) before antibody staining. For two-color fluorescence analysis (33) (double labeling) 1 × 106 to 1 × 107 cells were first incubated with 100–200 μl of LB3.1 (1:50 dilution of ascites) followed by three washes in 2-ml portions of PBS containing 1% FBS. The LB3.1 antibody was then labeled by incubation of cells with 25–50 μl of a 1:10 dilution of sheep F(ab')2 anti-mouse Ig-Texas red. After three washes (as above) cells were incubated with 200–300 μl of reconstituted FITC-conjugated MO2. Subsequently, cells were washed (three times), fixed in 2% formalin, and stored in the dark at 4°C.

Antibody staining of surface antigens was quantitatively analyzed with flow cytofluorometry on a Becton-Dickinson Dual Laser FACS 440 equipped with a Consort 40 data management system (Becton-Dickinson & Co.).

Statistical analysis. Statistical analysis of data was performed at the Core Lab Computer Facilities of Beth Israel Hospital, Boston. A t test was used to analyze the percentage monocytes expressing HLA-DR from normal individuals and patients with AIDS. A two-factor
Table I. Profile of Patients With AIDS

<table>
<thead>
<tr>
<th>Patients</th>
<th>Age (yr)</th>
<th>Risk group</th>
<th>WBC</th>
<th>%L</th>
<th>%M</th>
<th>Helper/suppressor (T4/T8 ratio)</th>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>39</td>
<td>Homosexual</td>
<td>3.2</td>
<td>12</td>
<td>6</td>
<td>0.15</td>
<td>Pneumocystis pneumonia Disseminated CMV</td>
</tr>
<tr>
<td>2</td>
<td>38</td>
<td>Homosexual</td>
<td>8.5</td>
<td>9</td>
<td>5</td>
<td>0.15</td>
<td>Pneumocystis pneumonia Mycobacterium avian intracellulare</td>
</tr>
<tr>
<td>3</td>
<td>34</td>
<td>Homosexual</td>
<td>3.2</td>
<td>6</td>
<td>7</td>
<td>0.20</td>
<td>Kaposi’s sarcoma Cryptosporidiosis</td>
</tr>
<tr>
<td>4</td>
<td>35</td>
<td>Bisexual</td>
<td>2.1</td>
<td>2</td>
<td>4</td>
<td>0.10</td>
<td>Pneumocystis pneumonia (two times) Mycobacterium avian intracellulare</td>
</tr>
<tr>
<td>5</td>
<td>34</td>
<td>Intravenous drug</td>
<td>2.4</td>
<td>10</td>
<td>5</td>
<td>0.14</td>
<td>Pneumocystis pneumonia Disseminated CMV Mycobacterium avian intracellulare</td>
</tr>
<tr>
<td>6</td>
<td>38</td>
<td>Intravenous drug</td>
<td>2.9</td>
<td>30</td>
<td>7</td>
<td>0.31</td>
<td>Pneumocystis pneumonia Disseminated CMV and HSV</td>
</tr>
<tr>
<td>7*</td>
<td>26</td>
<td>Homosexual</td>
<td>12.8</td>
<td>12</td>
<td>10</td>
<td>0.20</td>
<td>Pneumocystis pneumonia Recurrent candidiasis Recurrent genital herpes CNS toxoplasmosis Kaposi’s sarcoma</td>
</tr>
<tr>
<td>8</td>
<td>42</td>
<td>Homosexual</td>
<td>5.9</td>
<td>60</td>
<td>7</td>
<td>0.22</td>
<td>Kaposi’s sarcoma Pneumocystis pneumonia</td>
</tr>
<tr>
<td>9</td>
<td>45</td>
<td>Homosexual</td>
<td>3.6</td>
<td>23</td>
<td>9</td>
<td>0.14</td>
<td>Kaposi’s sarcoma Cryptosporidiosis</td>
</tr>
</tbody>
</table>

CNS, central nervous system. WBC, white blood cells. L, lymphocytes. M, monocytes. * At the time of our studies was receiving steroid therapy for CNS toxoplasmosis.

Because of the low cell recovery and because HLA-DR is present on both B cells and monocytes, we analyzed HLA-DR expression by indirect (two-antibody) labeling of LB3.1 (anti-HLA-DR) with Texas red fluorescent dye, whereas monocytes were identified by the use of FITC-conjugated MO2 antibody (MO2-FITC). We could simultaneously analyze, therefore, both cell surface markers and ascertain the percentage of monocytes expressing surface HLA-DR. This technique allowed us to quantitate HLA-DR expression on monocytes by analyzing only those cells that stained with the MO2 antibody.

The data presented in Table II were generated through study of adherent mononuclear cells obtained from a normal individual; the data demonstrate that the double staining
Table II. Two-Color Fluorescence Analysis of the Adherent Cells From Normal Peripheral Blood*

<table>
<thead>
<tr>
<th>Red staining</th>
<th>Green staining</th>
<th>Percentage of cells staining</th>
<th>Percentage HLA-DR-* within the total MO2-* population</th>
</tr>
</thead>
<tbody>
<tr>
<td>First antibody</td>
<td>Second antibody</td>
<td>FTAC-MO2</td>
<td>HLA-DR-*</td>
</tr>
<tr>
<td>LB3.1 (Anti-DR)</td>
<td>Texas red (sheep anti-mouse IgG)</td>
<td>+</td>
<td>6.1</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>27.8</td>
<td>77.0</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>5.3</td>
<td>4.0</td>
</tr>
<tr>
<td>−</td>
<td>+</td>
<td>98.8</td>
<td>14.0</td>
</tr>
</tbody>
</table>

* Normal cells were prepared from the Buffy coat cells of a normal donor. § In order to assess nonspecific staining, adherent cells were stained with OKT4 (like LB3.1, an IgG2b antibody), a helper T cell specific antibody. Staining of the adherent cell population by OKT4 ranged from 1.8 to 6.5%. § Percentages calculated from the analysis of 20,000 cells. In some cases summation of percentage values for all cell groups exceeded 100%. This occurred in the two-color analysis when cells fell on the border lines of windows used in defining negative, red, and green fluorescence. In these cases cells were counted twice resulting in values 0.8-1.9% > 100.

The technique can indeed facilitate study of HLA-DR upon MO2\-* cells. Staining with MO2-FITC resulted in 92.7\% MO2\-* cells; staining with LB3.1/Texas red resulted in 77.0\% HLA-DR\-* cells. Double staining for both determinants showed 68.6\% HLA-DR\/*MO2\*, 4\% HLA-DR\/*MO2\-, 24\% HLA-DR\-* / MO2\* , and 5.3\% HLA DR\/-MO2\-* cells. Among the doubly stained cells, 92.6\% (68.6 + 24.0) were MO2\*, 72.6\% (68.6 + 4.0) were HLA-DR\*, and the percentage HLA-DR\-* cells within the total MO2\-* population was 74.1\%. Background staining with Texas red in the absence of LB3.1 resulted in 1.6\% HLA-DR\-* cells. As nonspecific binding, especially through Fc-receptors, could be a problem in such an analysis we determined background staining with irrelevant antibodies. Substituting the subclass identical IgG2b T4 helper cell antibody for LB3.1 in the two-color staining protocol resulted in only 1-6\% of the MO2\-* cells staining red. Substitution of another IgM antibody (the anti-common acute lymphoblastic leukemia antigen, J13-FITC) for MO2-FITC resulted in 1-10\% of the adherent cells staining green. Hence, background staining, as determined with these nonmonocyte specific antibodies, was <10\%.

**HLA-DR expression in patients with AIDS.** Our initial studies using indirect staining of cells with single antibodies showed HLA-DR expressed on 81-94\% of adherent cells from four normal individuals. These data are in agreement with previously reported studies that cite values ranging between 75 and 90\% (34, 35). In one patient with AIDS with enough cells for quantitation it was determined that only 17\% of the adherent cells were HLA-DR\* in three other patients with AIDS the adherent cell population contained markedly fewer HLA-DR positive cells than in normal subjects.

To determine if the cells examined were monocytes and not contaminating B or T cells, and to allow us to use multiple stains on a small number of cells, we then used dual labeling techniques. All subsequent results were expressed in terms of the percentage of HLA-DR\-* cells among the MO2\-* population (Table II). The data derived from double staining of HLA-DR and MO2 on cells from eight normal individuals, four patients with lymphadenopathy, and six patients with AIDS is shown in Fig. 1.
Analysis of the normal individuals was performed on cells from six men and two women. For women the percentage of monocytes expressing HLA-DR was 88.0 and 61.4%. For normal individuals (Fig. 1) the mean±SD for the percentage of monocytes expressing HLA-DR was 72.9±15.1%. The range of these values was between 49.3 and 95.0%+. Only one individual had <50% HLA-DR+ monocytes (49.3%). Upon repeat analysis this individual showed 65.3% HLA-DR+ monocytes. In general, repeat analysis of other normal individuals showed modest variability. For example, in two different assays one individual had 95 and 83% HLA-DR+ monocytes, and another showed 65 and 79%+.

HLA-DR expression on monocytes from four patients with lymphadenopathy were similar or higher than those for normal subjects, with a range of HLA-DR+ monocytes between 58 to 97.4%, and mean±SD of 86.2±18.9% (Fig. 1). Three of these four analyzed patients had >90% HLA-DR+ monocytes. Of the six patients with AIDS, four had <50% HLA-DR+ monocytes (Fig. 1). The values had a range between 13.4 and 78.8%+ and a mean±SD of 46.2±22.0%. It was possible to repeat the analysis on only one of these patients; this patient initially had 43% HLA-DR+ monocytes and upon repeat, 24%.

As previously reported by Nunez and Stastny (34) we found that there was little change in HLA-DR expression on monocytes with up to 4 d of in vitro culture. After a 2-h adherence, the percentage of HLA-DR+ monocytes from three normal individuals was 75.3, 79.0, and 71.5. After 4 d in culture 61.4, 61.4, and 65.3%, respectively, of the cells expressed HLA-DR.

Sztein et al. (36) have reported, however, that monocyte cultures thoroughly depleted of nonadherent cells showed progressively decreased HLA-DR expression over 2–5 d of incubation. During the in vitro incubation nonadherent cells contaminating T cells may produce sufficient levels of IFN-γ for maintaining HLA-DR expression. We therefore investigated the T cell contamination of our monocyte cultures. The percentage of T cells present within the cultures was determined by cytofluorometry after staining with the phycoerythrin conjugate of the pan T cell-marker anti-Leu-1. For two normal individuals the percentages of cells found to be Leu-1+ were 4.3 and 8.1. For a patient with AIDS 0.59% of the cells stained with the anti-Leu-1 antibody.

To determine if the differences in HLA-DR expression observed in patients with AIDS and normal individuals resulted from a difference in contaminating T cells present within the adherent cell cultures we measured HLA-DR on MO2+ cells within the mononuclear leukocyte population without either adhering or culturing of the cells. For normal individuals the percentage of monocytes expressing HLA-DR was 76.5, 52.2, and 79.4. For two patients with lymphadenopathy 48.6 and 82.9% of the monocytes were HLA-DR+. In contrast, two patients with AIDS had 19.7 and 37.7% HLA-DR+ monocytes. These results are similar to our findings with adherent cells after 4 d of in vitro culture. Hence, these data suggest that the observed decrease in HLA-DR on monocytes from patients with AIDS does not result from in vitro culturing or from differences in T cells contaminating the cultures.

In addition, Belisio et al. (37) have recently shown, using specimens from skin biopsies, that patients with AIDS have a reduced expression of human Ia on Langerhans cells, the antigen-presenting cells of the skin. The number of Langerhans cells that expressed human Ia was ~37.0% that of the normal control group.

The observed decreases in human Ia expression on Langerhans cells and peripheral blood monocytes, two different populations of antigen presenting cells, therefore, supports the idea that we are measuring a defect that occurs in vivo as part of the immune deficiency syndrome of AIDS.

**In vitro effect of IFN-γ on HLA-DR expression.** Because of previous work indicating that IFN-γ was able to increase expression of class II antigens on monocytes (20–22), we treated monocytes with recombinant DNA-produced IFN-γ or a control supernatant for 48 h in vitro. A comparison of the IFN-γ treated with control treated cells shows that IFN-γ increased the percentage of MO2+ cells expressing HLA-DR (Table III). In the case of patients with AIDS, where HLA-DR expression was low, treatment with IFN-γ caused an increase in HLA-DR to near-normal levels (Table III). The average for

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Percentage cells staining</th>
<th>Percentage* within the MO2+ population</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HLA-DR+</td>
<td>MO2+</td>
</tr>
<tr>
<td>AIDS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medium</td>
<td>29.0</td>
<td>38.5</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>66.0</td>
<td>5.0</td>
</tr>
<tr>
<td>Medium</td>
<td>8.8</td>
<td>56.9</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>72.3</td>
<td>25.0</td>
</tr>
<tr>
<td>Medium</td>
<td>23.6</td>
<td>30.7</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>44.3</td>
<td>10.6</td>
</tr>
<tr>
<td>Normal subjects</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medium</td>
<td>60.6</td>
<td>8.3</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>73.1</td>
<td>15.5</td>
</tr>
<tr>
<td>Medium</td>
<td>73.8</td>
<td>15.5</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>89.9</td>
<td>2.0</td>
</tr>
<tr>
<td>Medium</td>
<td>80.0</td>
<td>4.2</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>92.0</td>
<td>6.4</td>
</tr>
<tr>
<td>Medium</td>
<td>44.8</td>
<td>24.1</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>59.4</td>
<td>2.0</td>
</tr>
<tr>
<td>Medium</td>
<td>40.4</td>
<td>41.6</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>54.4</td>
<td>13.1</td>
</tr>
</tbody>
</table>

*Analysis of variance (two factor adjusted for unequal sample size) showed the difference between AIDS and normal subjects was significant (P = 0.0017), as was the difference between IFN-γ and medium treated (P = 0.0013) for AIDS and normal subjects.
IFN-γ treated HLA-DR⁺ monocytes of patients was 82.7±9.5%, in comparison with 33.3%±17.2% HLA-DR⁺ monocytes for the medium control (Table III).

As previously reported we found that IFN-γ also increased HLA-DR expression on normal cells (20-22). With the exception of one individual who showed 95% HLA-DR⁺ monocytes in the absence of IFN-γ, IFN-γ increased HLA-DR expression with all other normal individuals (Table III). With normal subjects the average percentage of cells staining HLA-DR⁺ in the IFN-γ treated group was 96.0±2.1+ as compared with 76.1±18.7+ for monocytes maintained in the medium controls.

Most experiments were performed comparing the supernatant from the CHO line with the IFN-γ-containing plasmid with the supernatant from the non-plasmid-containing CHO line. Incubating adherent cells in cloned IFN-γ that had been further purified (>90%) resulted in similar increases in the expression of HLA-DR. Identical results were obtained using E. coli-produced human IFN-γ (obtained from Biogen Research Corp., Cambridge, MA).

**Discussion**

We have analyzed the HLA-DR expression on monocytes from normal individuals, homosexual males with lymphadenopathy, and patients with AIDS. The range of HLA-DR⁺ monocytes was 49.3 to 95% for normal individuals, 58 to 97.4% for patients with lymphadenopathy, and 13.4 to 78.8% for patients with AIDS (Fig. 1). The patients with AIDS are the first group of patients shown to have a deficiency in HLA-DR expression on monocytes. It is interesting that the incubation of AIDS monocytes with IFN-γ resulted in an increase in the percentage of monocytes expressing HLA-DR to values approaching those of normal individuals (74.3 to 93%+). At present, we do not know why some patients with AIDS show decreased HLA-DR and others fall within the normal range. We have examined only a small number of patients; thus, further studies are necessary to determine the percentage of patients who show decreased HLA-DR and to correlate this defect with other factors in AIDS.

Currently, therapeutic approaches to AIDS are attempting to correct the immunodeficiency by enhancing T cell activity. The effects of both interleukin-1 (secreted by monocytes) and interleukin-2 (IL-2), a product of T cells, are under study. In vitro, the addition of IL-2 was shown to augment both cytolytic T lymphocyte and natural killer cell responses in patients with AIDS (14).

Class II MHC molecules are prerequisite for antigen-presenting (accessory) cell function (23-27), and are instrumental in triggering the mixed lymphocyte (24) and graft-vs-host reactions (38). Three types of human Ia (class II MHC) molecules have been identified and biochemically characterized: DR, DS (or DC), and SB (39, 40). DR and SB molecules are structurally different but both show sequence homology with murine I-E molecules, whereas DS (DC) is homologous to mouse Ia (39, 40). Gonwa et al. (41) reported that a population of monocytes expressing both DR and DS (or DC) was more efficient in antigen presentation in autologous mixed lymphocyte reactions than were monocytes that expressed only the DR antigen. Whether the antigen responsible for the ability to interact with T cells is HLA-DR or the concomitantly expressed DS (DC) has not been established. Although we made no attempt in these studies to measure DS (DC) expression, immune interferon (IFN-γ) induces expression of both DR and DS (DC) antigens (20, 21, 42). Recent data indicate that IFN-γ may increase DS (DC) expression even more than DR (42). Also, we have not specifically examined different adherent cell subpopulations. It is possible that T cell function is affected by class II antigen expression on subpopulations of monocytes (41) or on dendritic cells (43).

In severe combined immunodeficiency of Arabian foals, a disease sharing features with severe combined immunodeficiency in children, elaboration, of IFN-γ by T cells is defective (44). It has been suggested that the IFN-γ defect may be responsible for the immunodeficiency. It is possible that a deficiency of class II positive monocytes, such as we found for patients with AIDS, and a resultant lack of T cell stimulation could eventually lead to a deficiency in secretion of IFN-γ.

A number of factors that regulate T cell immune responses, such as interferons and IL-2, are secreted by specific T cell subsets (45). In AIDS, secretion of such lymphokines may be greatly decreased. The production of IL-2 is defective in AIDS patients (14, 46) and it is noteworthy that IL-2 is the primary stimulus causing IFN-γ release from immune T cells (47-49). Murray et al. (50) have reported that the production of IFN-γ by mitogen-stimulated lymphocytes is also low in patients with AIDS. Hence, progressive T cell dysfunction may cause an IL-2 secretory defect leading in turn to an eventual IFN-γ secretory defect.

Thus, one explanation for our findings is that the deficiency in T cell secretion of IFN-γ results in decreased HLA-DR expression. A progressive defect in IL-2 release may culminate in a failure to elaborate IFN-γ. The IFN-γ secretory defect may result in low levels of class II antigen expression, which would cause severely impaired T cell responses to antigen. This scenario has the elements of a vicious circle. Hence, such a defect could be a major block in T cell responses to antigens which leaves patients vulnerable to an array of opportunistic infections. We are currently studying patients within the groups at high risk for development of AIDS to determine the relationship of the defect in macrophage expression of HLA-DR to other cellular deficits observed in AIDS. In addition we are now exploring the effects of administration of recombinant DNA-produced IFN-γ in AIDS patients. Further work will be necessary to determine if treatment (in vivo) with cloned IFN-γ will augment the T cell responses of patients with AIDS.

**Acknowledgments**

We are indebted to the Core Lab Computer Facilities, Beth Israel Hospital, supported in part by grant RR-01032 from the General
Clinical Research Centers Program of the Division of Research Resources, National Institutes of Health, for help with data analysis; Mr. Ed Luther, Brigham and Women's Hospital for operation of the FACS 440; Drs. R. Schooley and J. Groopman for providing patient materials; and Ms. Ann Marie Bynoe for excellent secretarial help.

This work was supported in part by National Institutes of Health grants AM 33929, AM 30105, CA19589, and CA34979. Robert Finberg is a Scholar of the Leukemia Society of America.

References


